Munich Reinsurance (1MUV2) Q2 2026 Earnings Report

The call presents strong financial and operating performance across multiple areas (net income, ROE, investment returns, Life & Health technical results, GSI and ERGO contributions, and a very strong solvency position). These positives are moderated by meaningful near-term reinsurance market headwinds: a EUR 2 billion reduction in reinsurance revenue guidance, rising normalized P&C combined ratios (around 82% and trending up), volume declines in July renewals (≈-9%) and reliance on favorable loss experience and markets. Management emphasizes disciplined underwriting, capital strength and diversification to manage the cycle and preserve earnings targets. On balance, the company appears well positioned but faces clear near-term top-line and P&C margin challenges that are being actively managed.

Munich Re said it remains on track to deliver Ambition 2030 while adjusting near‑term top‑line assumptions: group H1 net result was €3.9bn (already >60% of full‑year guidance) including a Q2 net profit of €2.2bn, and H1 ROE was 23% (vs Ambition target >18%); the group lowered reinsurance revenue guidance by €2bn to €38bn (from €40bn) while keeping ERGO revenue guidance at €24bn. Key operating metrics included P&C Re Q2 combined ratio 68.9% (reserve releases ≈6pp) and a six‑month combined ratio of 67.9%, though the normalized combined ratio rose to ~82% and is expected to trend up; a large structured transaction is contributing to this shift. GSI posted a Q2 combined ratio of 88.9% (H1 86.3%) with reported H1 revenue down ~3% but organic growth near the lower end of the 5–9% Ambition range. Life & Health Re delivered €528m total technical result in Q2 and >€1bn in H1, with a CSM stock of €16bn. Investment metrics were strong: Q2 return on investment 5.5% (H1 ROI 4.2%; full‑year guide >3.5%), running yield ~4.0% and reinvestment/new‑money around 4.3%; solvency remained very strong at >300% (304% in Q2). Management stressed disciplined underwriting, capital flexibility (dividends and buybacks) and confidence in achieving medium‑term ROE and >8% average annual EPS growth.